Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines

Introduction to GPP: Why Ethical Publication Matters

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).

These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.

Core Principles of GPP3

GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:

• Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
• Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
• Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
• Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
• Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.

These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA, and WHO registries.

Authorship Ethics: Avoiding Misconduct

One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:

• Substantial contribution to study design, data analysis, or interpretation
• Drafting or revising the article critically for intellectual content
• Approval of the final version for publication
• Accountability for the accuracy and integrity of the published content

GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.

Managing Sponsor Involvement and Independence

Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:

• Allowing authors full access to data or summary-level analyses
• Refraining from controlling the publication’s message or conclusions
• Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
• Ensuring transparency about editorial assistance from medical writers

Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.

Publication Planning and Documentation

Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:

• A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
• A list of planned abstracts, posters, and manuscripts
• Defined roles and responsibilities for each author and contributor
• A process for conflict resolution and content approval

Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.

External Guidelines Complementing GPP

GPP guidelines work in tandem with several other international frameworks:

• EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
• FDAAA 801: Mandates results reporting on ClinicalTrials.gov
• ICMJE: Sets criteria for authorship and trial registration
• WHO ICTRP: Advocates for global result disclosure standards

GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.

Role of Medical Writers and Review Committees

Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:

• Documentation of writing contributions in the manuscript or submission form
• Verification that writers had no role in data manipulation or outcome shaping
• Confirmation that writers received direction from authors, not solely from the sponsor

Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.

Common Violations and Their Consequences

GPP violations can lead to severe reputational and regulatory consequences. Common violations include:

• Failing to disclose sponsor involvement
• Publishing only favorable outcomes (publication bias)
• Suppressing trial data or delaying negative result publication
• Adding honorary or ghost authors
• Not declaring writer contributions or financial support

Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.

Conclusion: Making GPP a Standard Practice

The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.

As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.

Creating Clear and Compliant Lay Summaries of Clinical Trial Results

Introduction: Why Lay Summaries Matter

Lay summaries—also called plain language summaries—are short, readable documents that communicate the results of a clinical trial to the general public. Required under the EU Clinical Trials Regulation (EU CTR), and encouraged globally, lay summaries increase transparency, uphold participant rights, and promote public understanding of clinical research.

Unlike technical study reports or journal articles, lay summaries must be free of jargon, written at a B1/B2 reading level, and structured to clearly explain what was done, what was found, and what it means. This article outlines the formatting standards, timelines, structure, and tools for writing effective and compliant lay summaries.

EU CTR Requirements for Lay Summaries

Under Regulation (EU) No. 536/2014, all interventional trials conducted in the EU must include a lay summary submitted through the Clinical Trials Information System (CTIS). Key requirements include:

• Deadline: Submitted within 12 months of trial completion (6 months for pediatric trials)
• Format: Uploaded as a PDF to CTIS, alongside technical results
• Language: In the official language(s) of each participating country
• Structure: Follows EMA-recommended 10-section format (see below)

Lay summaries are published automatically unless a justified deferral is approved, making readability and content accuracy critically important.

10 Recommended Sections of a Lay Summary (EMA Template)

The European Medicines Agency (EMA) suggests the following structure for lay summaries:

1. Trial Identifier: Trial number, title, and registry ID (e.g., EudraCT)
2. Purpose of the Trial: The disease and objective of the study
3. Who Participated: Summary of participant demographics and criteria
4. What Treatment Was Given: Interventions and how they were administered
5. What Was Measured: Primary and secondary outcomes
6. Results of the Trial: Key findings with simple visuals or percentages
7. Side Effects: Common and serious adverse events explained in lay terms
8. Conclusion: What the findings mean for future care or research
9. Where to Learn More: Trial registry links and sponsor contact info
10. Glossary: Definitions of any unavoidable medical terms

Each section should be 2–4 paragraphs and use short, direct sentences for clarity.

Readability and Language Expectations

Lay summaries must be written at a B1/B2 CEFR level, equivalent to an 8th-grade reading level. This ensures accessibility to most of the general population. Tips for maintaining proper readability include:

• Use active voice and avoid passive constructions
• Replace technical terms with simpler alternatives (e.g., “high blood pressure” instead of “hypertension”)
• Limit sentence length to 15–20 words
• Use bulleted or numbered lists where appropriate
• Define complex words in parentheses or glossary

Free tools like Hemingway Editor, Readable.com, and Microsoft Word’s built-in readability checker can assess compliance with B-level standards.

Visual Aids and Formatting

Visuals enhance comprehension for lay readers. When permitted by the registry, include:

• Simple bar charts or pie charts for results comparison
• Infographics to explain trial flow or study design
• Color-coded adverse event severity graphs

Always ensure images are captioned, accessible, and printable in grayscale. Avoid clinical imagery that may cause confusion or concern.

Translation for Multinational Trials

If a trial is conducted across multiple EU member states, the lay summary must be submitted in all applicable official languages. Considerations include:

• Using certified medical translators familiar with plain language principles
• Conducting back-translations to verify accuracy
• Adding region-specific terminology if relevant

In some cases, translation costs and workflows can be centralized using CROs or localization vendors with EU CTR experience.

Timeline Integration and Planning

Lay summaries should be written before the trial completes, so they’re ready for submission alongside the technical results. Planning tips:

• Assign summary drafting to medical writers or patient engagement experts
• Use a shared template across all trials for consistency
• Pre-fill non-result sections (e.g., trial purpose, eligibility) early
• Set internal deadlines at least 30 days before CTIS submission deadlines

Late or missing lay summaries can delay trial publication in CTIS and trigger regulatory attention.

Common Mistakes and How to Avoid Them

• Overuse of jargon: Even common clinical terms may be unfamiliar to the public
• Incomplete safety explanations: Explain both minor and serious side effects clearly
• Neglecting the “what it means” section: Readers need context, not just numbers
• Too short or too long summaries: 4–6 pages total is ideal
• Missing trial ID or registry link: Required for public verification

Review summaries with patient advocates or advisory boards for clarity before submission.

Best Practices Checklist

• Use EMA’s 10-section structure
• Write at CEFR B1/B2 level
• Submit within 12 months of trial completion
• Provide multilingual versions for EU states
• Review with a non-specialist reader before submission
• Link to registry and sponsor contact for questions

These practices ensure legal compliance, ethical communication, and meaningful public engagement with clinical research.

Conclusion: Lay Summaries Empower Public Trust

Lay summaries are a key component of modern trial transparency. More than a regulatory checkbox, they are a public-facing commitment to clear, honest, and accessible science. Well-prepared lay summaries demonstrate respect for participants, accountability to the public, and alignment with international transparency goals.

Sponsors that prioritize early, accurate, and well-written lay summaries stand out not just for compliance—but for their credibility, ethics, and public impact.